Manatuck Hill Partners’s Trueblue TBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-30,000
Closed -$252K 127
2024
Q4
$252K Buy
+30,000
New +$232K 0.1% 99
2023
Q3
Sell
-20,000
Closed -$354K 138
2023
Q2
$354K Buy
+20,000
New +$339K 0.17% 84
2023
Q1
Sell
-25,519
Closed -$500K 117
2022
Q4
$500K Sell
25,519
-1,481
-5% -$30K 0.24% 70
2022
Q3
$515K Buy
+27,000
New +$546K 0.26% 63
2022
Q2
Sell
-110,200
Closed -$3.18M 129
2022
Q1
$3.18M Buy
110,200
+49,900
+83% +$1.37M 1.24% 24
2021
Q4
$1.67M Buy
+60,300
New +$1.71M 0.63% 47

Other funds holding TBI

Manatuck Hill Partners's TBI Position: Q1 2025 in Review

Manatuck Hill Partners sold out of Trueblue (TBI) in Q1 2025, closing a stake of 30,000 shares — an estimated $252K sold.

Manatuck Hill Partners first reported a position in TBI in Q4 2021 and held it in 6 quarters. The position peaked at $3.18M in Q1 2022. 112 funds tracked by Wall St. Rank hold TBI as of Q1 2025.

  • Manatuck Hill Partners reported no remaining Trueblue position as of Q1 2025 after selling out during the quarter.
  • Manatuck Hill Partners sold 30,000 Trueblue shares in Q1 2025, an estimated $252K.
  • Manatuck Hill Partners first reported a position in Trueblue in Q4 2021 and held it in 6 quarters.
  • Manatuck Hill Partners's Trueblue position peaked at $3.18M in Q1 2022.
  • 112 funds tracked by Wall St. Rank held Trueblue as of Q1 2025.

Based on Manatuck Hill Partners's 13F filing for Q1 2025, filed 15 May 2025.